ElyssaMed develops first therapeutic treatment composed of several antigenic peptides specific to lung cancer or non-small-cell lung for the general public, from the CTPP and an adjuvant in vaccines already marketed for humans. This product once administered to lung cancer patients, will amplify their specific immune response against tumor cells expressing the antigen CTPP to lead to their destruction.
The company plans to implement its first candidate drug to other cancers with always in sight cancer (over) expressing CTPP.
Among these cancers, including cancers classified "orphan diseases", such as:
• Cancers Small Cell Bronchial
• Cancers Thyroid medullary
• Neuroendocrine tumors